Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
Amandine Desette, Pierre-Olivier Guichet, Sheik Emambux, Konstantin Masliantsev, Ulrich Cortes, et al.. Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16 (5), pp.757-782. ⟨10.1016/j.jcmgh.2023.07.008⟩. ⟨hal-04302791⟩
Mots clés
Anti-PD-1 antibody
Androgen insensitivity
Cutaneous squamous cell carcinoma
Immune checkpoint inhibitor
Cancer bronchique non à petites cellules
Brain Metastases
Immunohistochemistry
Bariatric surgery
BRAFV600E
Radiotherapy
Merkel cell carcinoma
Langerhans cell histiocytosis
Safety
CARMN
Allelic imbalance
Histiocytosis
Advanced
BRAF
Sonic Hedgehog
Abscopal effect
Anti-PD1 blockade
Advanced melanoma
Anti-CTLA-4
BRAFV600E mutation
Colorectal cancer
Metastatic cSCC
Plasma
EGFR
TNM classification
Chemoresistance
AZD9291
Anti-PD-1
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Colorectal carcinoma
Prevention
Adjuvant FOLFOX
Treatment
Anti-Tumor pharmacology
ACTH
Abdominal pain
Survival
Antibody-drug conjugate
Immunotherapy
Polyomavirus
Antineoplastic agents
Acute generalized exanthematous pustulosis
Adjuvant therapy
Prognostic
Metastatic
Resistance
Immunomodulation
Chemotherapy
Osimertinib
Dabrafenib
Melanoma
Locally advanced
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Molecular targeted therapies
AML
Mesenchymal stromal cells
Prognosis
Surgical excision
Biliopancreatic diversion
Staging
Body mass index
Radiofrequency ablation
BRAFV600-mutant melanoma
Cancer
Circulating cell-free DNA
Wnt
Targeted therapy
Biomarkers
Colon cancer
ALK
BRAF V600-mutation
Circulating tumor DNA
Adjuvant
Invasive cutaneous squamous cell carcinoma
Gastric bypass
Beta-catenin
Diagnosis
Systemic therapy
Crizotinib
C797S
2-chlorodeoxyadenosine
ADN tumoral circulant
Cemiplimab
Adverse events
Anti-PD1
Lung adenocarcinoma
Trametinib
Nivolumab
Non-small cell lung cancer
Biomarker
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
ALK rearrangement
Follow-up
BRAF V600E
Bone marrow niche
Children